Skip to main content

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model




) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.8%. By the end of trading, Incyte fell $0.48 (-2.1%) to $22.02 on light volume. Throughout the day, 519,786 shares of Incyte exchanged hands as compared to its average daily volume of 1,521,300 shares. The stock ranged in price between $21.89-$22.75 after having opened the day at $22.57 as compared to the previous trading day's close of $22.50. Other companies within the Health Care sector that declined today were:

Five Star Quality Care Incorporated



), down 16.8%,

Auxilium Pharmaceuticals



), down 12.7%,

Lexicon Pharmaceuticals



), down 11.0% and

Aastrom Biosciences



), down 10.9%.

  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. Incyte has a market cap of $3.1 billion and is part of the drugs industry. Shares are up 37.1% year to date as of the close of trading on Friday.

TheStreet Ratings rates Incyte as a


. Among the areas we feel are negative, one of the most important has been poor profit margins.

On the positive front,

Galectin Therapeutics



), down 20.0%,




), down 19.5%,

Nymox Pharmaceutical Corporation



), down 13.2% and




), down 12.9% , were all gainers within the health care sector with




) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care




Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.